

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
11 June 2020 (11.06.2020)



(10) International Publication Number
WO 2020/115371 A1

(51) International Patent Classification:

C07J 41/00 (2006.01) A61K 31/58 (2006.01)
C07J 43/00 (2006.01) A61P 35/00 (2006.01)
C07J 71/00 (2006.01)

(21) International Application Number:

PCT/FI2019/050874

(22) International Filing Date:

05 December 2019 (05.12.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

20186056 05 December 2018 (05.12.2018) FI

(71) Applicant: FORENDO PHARMA LTD [FI/FI]; Itäinen
Pitkätatu 4 B, 20520 Turku (FI).

(72) Inventors: HIRVELÄ, Leena; c/o Forendo Pharma Ltd,
Itäinen Pitkätatu 4 B, 20520 Turku (FI). HAKOLA, Mar-
jo; c/o Forendo Pharma Ltd, Itäinen Pitkätatu 4 B, 20520
Turku (FI). LINNANEN, Tero; c/o Forendo Pharma Ltd,
Itäinen Pitkätatu 4 B, 20520 Turku (FI). KOSKIMIES,
Pasi; c/o Forendo Pharma Ltd, Itäinen Pitkätatu 4 B, 20520
Turku (FI). STJERNSCHANTZ, Camilla; c/o Forendo
Pharma Ltd, Itäinen Pitkätatu 4 B, 20520 Turku (FI).

(74) Agent: KOLSTER OY AB; (Salmisaarenaukio 1),
P.O.Box 204, 00181 Helsinki (FI).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))
— before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))
— in black and white; the international application as filed
contained color or greyscale and is available for download
from PATENTSCOPE

(54) Title: ESTRA-1,3,5(10)-TRIENE COMPOUNDS CONDENSED IN POSITION 16(17) WITH A PYRAZOLE RING AS IN-
HIBITORS OF 17-HSD1



(57) Abstract: The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof (I) wherein R1 to R4 are as defined in the claims. The invention further relates to their use as inhibitors of 17 β -HSD1 and in treatment or prevention of steroid hormone dependent dis-eases or disorders, such as steroid hormone dependent dis-eases or disorders requiring the inhibition of the 17 β -HSD1 enzyme and/or requiring the lowering of the endogenous estradiol concentration. The present invention also relates to the preparation of the aforementioned compounds and to pharmaceutical compositions comprising as an active ingredient(s) one or more of the aforementioned compounds or pharmaceutically acceptable salts thereof.

WO 2020/115371 A1